Evaluation of the NovaLisa™ <i>Leishmania Infantum</i> IgG ELISA in A Reference Diagnostic Laboratory in A Non-Endemic Country

Anti-<i>Leishmania</i> antibodies may be detectable in patients with leishmaniasis. Here, we compared a commercial enzyme-linked immunosorbent assay (ELISA) for the detection of anti-<i>Leishmania</i> antibodies, with an immunofluorescence antibody test (IFAT) that is no long...

Full description

Bibliographic Details
Main Authors: Christen Rune Stensvold, Amalie Vang Høst, Salem Belkessa, Henrik Vedel Nielsen
Format: Article
Language:English
Published: MDPI AG 2019-02-01
Series:Antibodies
Subjects:
Online Access:https://www.mdpi.com/2073-4468/8/1/20
id doaj-26acda666b594110a62cbadd30138338
record_format Article
spelling doaj-26acda666b594110a62cbadd301383382020-11-25T01:51:36ZengMDPI AGAntibodies2073-44682019-02-01812010.3390/antib8010020antib8010020Evaluation of the NovaLisa™ <i>Leishmania Infantum</i> IgG ELISA in A Reference Diagnostic Laboratory in A Non-Endemic CountryChristen Rune Stensvold0Amalie Vang Høst1Salem Belkessa2Henrik Vedel Nielsen3Department of Bacteria, Parasites &amp; Fungi, Statens Serum Institut, Artillerivej 5, DK–2300 Copenhagen S, DenmarkDepartment of Bacteria, Parasites &amp; Fungi, Statens Serum Institut, Artillerivej 5, DK–2300 Copenhagen S, DenmarkDepartment of Bacteria, Parasites &amp; Fungi, Statens Serum Institut, Artillerivej 5, DK–2300 Copenhagen S, DenmarkDepartment of Bacteria, Parasites &amp; Fungi, Statens Serum Institut, Artillerivej 5, DK–2300 Copenhagen S, DenmarkAnti-<i>Leishmania</i> antibodies may be detectable in patients with leishmaniasis. Here, we compared a commercial enzyme-linked immunosorbent assay (ELISA) for the detection of anti-<i>Leishmania</i> antibodies, with an immunofluorescence antibody test (IFAT) that is no longer commercially available. Eighty-six serum samples from 73 patients were tested. The results obtained by the NovaLisa&#8482; <i>Leishmania infantum</i> IgG ELISA, interpreted according to the instructions of the manufacturer, but with a modified cut-off for borderline positive values, were compared with the IFAT results that were already available. Moreover, <i>Leishmania</i> Western blot IgG results were available for 43 of the samples. The overall concordance of ELISA and IFAT was 67%. The ELISA and IFAT tests scored as 24% and 15% of the samples being positive, respectively, while 13% and 33% scored as borderline-positive, respectively. Using a Western blot (WB) as the reference, the sensitivities and specificities for the positive plus borderline-positive samples combined was 95.5% (95% confidence interval (CI), 77.2&#8315;99.9%) and 81.0% (95% CI, 58.1&#8315;94.6%) for ELISA, and 95.5% (95% CI, 77.2&#8315;99.9%) and 42.9% (95% CI, 21.8&#8315;66.0%) for IFAT, respectively. Overall, the ELISA proved to be a cost-effective alternative to the IFAT, due to its higher accuracy and specificity, and with a consequently lower number of confirmatory WB tests being required. Lastly, we also present data on the associations between seroconversion and the type of leishmaniasis.https://www.mdpi.com/2073-4468/8/1/20parasiteclinical microbiologyvector-borne diseaseleishmaniasisdiagnosisdiagnostic methodsmolecular epidemiology
collection DOAJ
language English
format Article
sources DOAJ
author Christen Rune Stensvold
Amalie Vang Høst
Salem Belkessa
Henrik Vedel Nielsen
spellingShingle Christen Rune Stensvold
Amalie Vang Høst
Salem Belkessa
Henrik Vedel Nielsen
Evaluation of the NovaLisa™ <i>Leishmania Infantum</i> IgG ELISA in A Reference Diagnostic Laboratory in A Non-Endemic Country
Antibodies
parasite
clinical microbiology
vector-borne disease
leishmaniasis
diagnosis
diagnostic methods
molecular epidemiology
author_facet Christen Rune Stensvold
Amalie Vang Høst
Salem Belkessa
Henrik Vedel Nielsen
author_sort Christen Rune Stensvold
title Evaluation of the NovaLisa™ <i>Leishmania Infantum</i> IgG ELISA in A Reference Diagnostic Laboratory in A Non-Endemic Country
title_short Evaluation of the NovaLisa™ <i>Leishmania Infantum</i> IgG ELISA in A Reference Diagnostic Laboratory in A Non-Endemic Country
title_full Evaluation of the NovaLisa™ <i>Leishmania Infantum</i> IgG ELISA in A Reference Diagnostic Laboratory in A Non-Endemic Country
title_fullStr Evaluation of the NovaLisa™ <i>Leishmania Infantum</i> IgG ELISA in A Reference Diagnostic Laboratory in A Non-Endemic Country
title_full_unstemmed Evaluation of the NovaLisa™ <i>Leishmania Infantum</i> IgG ELISA in A Reference Diagnostic Laboratory in A Non-Endemic Country
title_sort evaluation of the novalisa™ <i>leishmania infantum</i> igg elisa in a reference diagnostic laboratory in a non-endemic country
publisher MDPI AG
series Antibodies
issn 2073-4468
publishDate 2019-02-01
description Anti-<i>Leishmania</i> antibodies may be detectable in patients with leishmaniasis. Here, we compared a commercial enzyme-linked immunosorbent assay (ELISA) for the detection of anti-<i>Leishmania</i> antibodies, with an immunofluorescence antibody test (IFAT) that is no longer commercially available. Eighty-six serum samples from 73 patients were tested. The results obtained by the NovaLisa&#8482; <i>Leishmania infantum</i> IgG ELISA, interpreted according to the instructions of the manufacturer, but with a modified cut-off for borderline positive values, were compared with the IFAT results that were already available. Moreover, <i>Leishmania</i> Western blot IgG results were available for 43 of the samples. The overall concordance of ELISA and IFAT was 67%. The ELISA and IFAT tests scored as 24% and 15% of the samples being positive, respectively, while 13% and 33% scored as borderline-positive, respectively. Using a Western blot (WB) as the reference, the sensitivities and specificities for the positive plus borderline-positive samples combined was 95.5% (95% confidence interval (CI), 77.2&#8315;99.9%) and 81.0% (95% CI, 58.1&#8315;94.6%) for ELISA, and 95.5% (95% CI, 77.2&#8315;99.9%) and 42.9% (95% CI, 21.8&#8315;66.0%) for IFAT, respectively. Overall, the ELISA proved to be a cost-effective alternative to the IFAT, due to its higher accuracy and specificity, and with a consequently lower number of confirmatory WB tests being required. Lastly, we also present data on the associations between seroconversion and the type of leishmaniasis.
topic parasite
clinical microbiology
vector-borne disease
leishmaniasis
diagnosis
diagnostic methods
molecular epidemiology
url https://www.mdpi.com/2073-4468/8/1/20
work_keys_str_mv AT christenrunestensvold evaluationofthenovalisaileishmaniainfantumiiggelisainareferencediagnosticlaboratoryinanonendemiccountry
AT amalievanghøst evaluationofthenovalisaileishmaniainfantumiiggelisainareferencediagnosticlaboratoryinanonendemiccountry
AT salembelkessa evaluationofthenovalisaileishmaniainfantumiiggelisainareferencediagnosticlaboratoryinanonendemiccountry
AT henrikvedelnielsen evaluationofthenovalisaileishmaniainfantumiiggelisainareferencediagnosticlaboratoryinanonendemiccountry
_version_ 1724997451938529280